Skip To Main Content
Gunther Kauselmann on Muck Rack

Gunther Kauselmann

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gunther

Contact Gunther, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial - Nature Communications

|
By Janine Kutzsche, Marlene Pils, Dieter Willbold, Gunther Kauselmann, Friederike Fenski
| Nature Verified
Abstract Self-replicating amyloid beta (Aβ) oligomers are considered as one of the major drivers for disrupted synaptic function and plasticity, leading to impaired neuronal viability and progression of Alzheimer’s disease (AD). Here, we investigated the safety, tolerability and pharmacokinetics of the anti-oligomeric peptide PRI-002, which was developed to disassemble toxic Aβ oligomers into non-toxic monomers.
Open in Who Shared Issue with article?
See all 1 articles